Antineoplastic activity of lentiviral vectors expressing interferon-alpha in a preclinical model of primary effusion lymphoma

Blood. 2009 May 7;113(19):4525-33. doi: 10.1182/blood-2008-09-180307. Epub 2009 Feb 4.

Abstract

The peculiar site of development of primary effusion lymphoma (PEL) highlights a specific role of body cavities in the pathogenesis of this neoplasia. We used a xenograft murine model of PEL to characterize the contribution of the host microenvironment to PEL growth. The activity of a murine (ie, host-specific) interferon-alpha(1) (IFN-alpha(1))-expressing lentiviral vector (mIFN-alpha(1)-LV) was compared with that of a human (h) IFN-alpha(2)b-LV. LVs efficiently delivered the transgene to PEL cells and conferred long-term transgene expression in vitro and in vivo. Treatment of PEL-injected severe combined immunodeficiency mice with hIFN-alpha(2)b-LV significantly prolonged mice survival and reduced ascites development. Interestingly, mIFN-alpha(1)-LV showed an antineoplastic activity comparable with that observed with hIFN-alpha(2)b-LV. As mIFN-alpha(1) retained species-restricted activity in vitro, it probably acted in vivo on the intracavitary murine milieu. mIFN-alpha(1)-treated murine mesothelial cells were found to express tumor necrosis factor-related apoptosis-inducing ligand and to significantly trigger apoptosis of cocultured PEL cells in a tumor necrosis factor-related apoptosis-inducing ligand-dependent manner. These data suggest that the interaction between lymphomatous and mesothelial cells lining the body cavities may play a key role in PEL growth control and also indicate that the specific targeting of microenvironment may impair PEL development.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use*
  • Cells, Cultured
  • Cytokines / metabolism
  • Drug Evaluation, Preclinical
  • Female
  • Genetic Vectors*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / therapeutic use*
  • Kidney / cytology
  • Kidney / drug effects
  • Kidney / metabolism
  • Lentivirus / genetics*
  • Lymphoma, Primary Effusion / drug therapy*
  • Lymphoma, Primary Effusion / genetics
  • Lymphoma, Primary Effusion / pathology
  • Mesoderm / cytology
  • Mesoderm / drug effects
  • Mesoderm / metabolism
  • Mice
  • Mice, SCID
  • Peritoneum / cytology
  • Peritoneum / drug effects
  • Peritoneum / metabolism
  • Recombinant Proteins

Substances

  • Antineoplastic Agents
  • Cytokines
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins